Form 4: Inari Medical CEO Andrew Hykes Sells Shares Under 10b5-1 Trading Plan

Inari Medical's CEO, Andrew Hykes, sold 3,000 shares of common stock on December 20, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Andrew Hykes, the President and CEO of Inari Medical, Inc., sold a total of 3,000 shares of the company's common stock on December 20, 2024.
• The sales were executed in multiple trades at weighted average prices of $55.20 and $55.65 per share.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted by Mr. Hykes on November 13, 2023.
• Following these sales, Mr. Hykes directly owns 439,310 shares of Inari Medical common stock.
• He also indirectly owns 1,550 shares through each of his three children and 1,000 shares through his spouse.

Sentiment

Score: 5

Explanation: The document reports a routine stock sale by the CEO under a pre-arranged plan, which is neither particularly positive nor negative. It's a neutral event from an investment perspective.

Risks

• Sales by company insiders, even under pre-arranged plans, can sometimes be perceived negatively by the market.

Industry Context

Insider trading activity is a common occurrence in publicly traded companies, and sales under 10b5-1 plans are a routine way for executives to manage their personal finances while avoiding accusations of trading on non-public information.

Comparison to Industry Standards

• Sales by executives under 10b5-1 plans are a common practice across the industry, including companies like Medtronic, Boston Scientific, and Abbott, which also have executives who regularly sell shares under similar plans.
• The volume of shares sold by Mr. Hykes is relatively small compared to the total outstanding shares of Inari Medical, and is not unusual for executives managing their personal portfolios.

Stakeholder Impact

• The stock sale may have a minor impact on shareholder sentiment, but is unlikely to significantly affect the company's operations or financial health.

Key Dates

Keywords

Inari Medical, Andrew Hykes, insider trading, Form 4, Rule 10b5-1, stock sale, executive compensation